secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cullinan Therapeutics, Inc. (CGEM)
CIK:        0001789972
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0000950170-25-066382
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cullinan Q1 net loss $48.5M; CLN-978 gains EMA approval for RA, expands into Sjögren's
--------------------------------------------------------------------------------

- Net loss of $48.5M in Q1 2025 vs $37.1M in Q1 2024; R&D expenses rose to $41.5M.
- Cash and investments $567.4M as of March 31, 2025; runway into 2028 reaffirmed.
- EMA approved Phase 1 study of CLN-978 in active, difficult-to-treat rheumatoid arthritis; to start Q2 2025.
- CLN-978 Phase 1 in Sjögren's disease to initiate in U.S. in Q2 2025; SLE data expected Q4 2025.
- CLN-619 discontinued in gynecological cancers; zipalertinib REZILIENT1 results at ASCO June 1.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1789972/000095017025066382/0000950170-25-066382-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1789972/000095017025066382/cgem-20250508.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-066382

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer